BioLineRx Ltd.
BLRX
$3.28
-$0.06-1.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -91.36% | -94.36% | -96.28% | 144.77% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -91.36% | -94.36% | -96.28% | 144.77% | -- |
| Cost of Revenue | -89.78% | -91.97% | -97.66% | 64.92% | -- |
| Gross Profit | -91.68% | -94.84% | -95.91% | 410.83% | -- |
| SG&A Expenses | -88.03% | -97.40% | -87.20% | -29.43% | -27.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -74.50% | -76.65% | -77.34% | -10.47% | -16.40% |
| Operating Income | 59.03% | 60.11% | 50.41% | 73.28% | 56.41% |
| Income Before Tax | 83.22% | -914.05% | 836.64% | 77.05% | 63.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 83.22% | -914.05% | 836.64% | 77.05% | 63.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 83.22% | -914.05% | 836.64% | 77.05% | 63.66% |
| EBIT | 59.03% | 60.11% | 50.41% | 73.28% | 56.41% |
| EBITDA | 54.08% | 59.85% | 43.29% | 82.79% | 62.53% |
| EPS Basic | 91.84% | -525.00% | 483.33% | 81.40% | 71.51% |
| Normalized Basic EPS | 93.33% | -433.33% | 450.00% | 78.57% | 72.22% |
| EPS Diluted | 91.84% | -525.00% | 483.33% | 81.40% | 71.51% |
| Normalized Diluted EPS | 93.33% | -433.33% | 450.00% | 78.57% | 72.22% |
| Average Basic Shares Outstanding | 117.35% | 97.87% | 104.10% | 21.30% | 29.11% |
| Average Diluted Shares Outstanding | 117.35% | 97.87% | 104.10% | 21.30% | 29.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |